Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/9309
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cooper, Mark E | en |
dc.contributor.author | Webb, R L | en |
dc.contributor.author | de Gasparo, M | en |
dc.date.accessioned | 2015-05-15T22:21:36Z | |
dc.date.available | 2015-05-15T22:21:36Z | |
dc.date.issued | 2001 | en |
dc.identifier.citation | Cardiovascular Drug Reviews; 19(1): 75-86 | en |
dc.identifier.govdoc | 11314602 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/9309 | en |
dc.description.abstract | This review deals with similarities and differences between the effects of ACE inhibitors and AT1-receptor blockers in the kidney. Specific receptor blockade has demonstrated that the beneficial effects of AT1 blockers arise from two mechanisms: the reduction of the AT1 receptor mediated response and the increase in plasma levels of Ang II through the AT1-receptor blockade, which leads to increased stimulation of the AT2 receptor (the so-called yin-yang effect). Both ACE inhibition and AT1-receptor blockade provide significant renal protection in the majority of experimental animal models of kidney diseases. AT1 receptor blockade may offer additional clinical benefits over ACE inhibitor treatment, particularly in the kidney, where AT1-receptor blockade does not cause the fall in glomerular filtration rate seen with ACE inhibitor treatment. A number of long-term clinical studies currently running should show the real value of this new class of compounds in the management of hypertension and associated cardiorenal diseases. | en |
dc.language.iso | en | en |
dc.subject.other | Angiotensin II.blood | en |
dc.subject.other | Angiotensin Receptor Antagonists | en |
dc.subject.other | Angiotensin-Converting Enzyme Inhibitors.pharmacology.therapeutic use | en |
dc.subject.other | Animals | en |
dc.subject.other | Diabetes Mellitus.drug therapy.physiopathology | en |
dc.subject.other | Disease Models, Animal | en |
dc.subject.other | Humans | en |
dc.subject.other | Hypertension.drug therapy | en |
dc.subject.other | Kidney.drug effects.metabolism | en |
dc.subject.other | Kidney Diseases.prevention & control | en |
dc.subject.other | Kidney Failure, Chronic.drug therapy | en |
dc.subject.other | Rats | en |
dc.subject.other | Receptor, Angiotensin, Type 1 | en |
dc.subject.other | Receptor, Angiotensin, Type 2 | en |
dc.title | Angiotensin receptor blockers and the kidney: possible advantages over ACE inhibition? | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Cardiovascular drug reviews | en |
dc.identifier.affiliation | University of Melbourne, Department of Medicine, Austin and Repatriation Medical Center, West Heidelberg, Victoria, Australia | en |
dc.description.pages | 75-86 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/11314602 | en |
dc.type.austin | Journal Article | en |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.